You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
樂普醫療(300003.SZ):藥物塗層冠脈球囊導管獲得NMPA註冊批准
格隆匯 06-12 20:29

格隆匯6月12日丨樂普醫療(300003.SZ)公佈,公司於今日獲悉,公司自主研發的“藥物塗層冠脈球囊導管”(Vesselin)獲得國家藥品監督管理局的註冊批准,取得《醫療器械註冊證》(國械注準20203030561)

心血管介入治療已走向介入無植入時代,目前實現介入無植入的核心治療品主要包括可降解支架和藥物球囊。“藥物塗層冠脈球囊導管”是“生物可吸收支架(NeoVas)”上市後公司推進心血管介入治療走向介入無植入時代的重產品之一,將對公司醫療器械領域經營發展產生重大影響。該產品的上市,將進一步提升公司在心血管領域的核心競爭力,帶動器械板塊營收持續增長,進一提高創新產品的收入和利潤佔比,保障公司業績持續穩定增長。公司將持續大研發投入,為介入無植入目標的實現,提供滿足各種適應症需求的介入無植入治療產品,同時研發實現介入無植入的各種輔助導管和腔內檢驗導管及器械,滿足患者不同適應症不同疾病的治療需求。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account